medigraphic.com
Boletín Clínico de la Asociación Médica del Hospital Infantil del Estado de Sonora

2025, Number 2

<< Back Next >>

Bol Clin Hosp Infant Edo Son 2025; 42 (2)

Stevens-Johnson/Toxic Epidermal necrolysis overlap in a newborn with Gastroschisis: case report

Torres GIG, Oroz GFG, Corella OLF, Rascón AA, Aguirre MMF, Martínez CÉM

Language: Spanish
References: 10
Page: 36-39
PDF size: 202.79 Kb.


ABSTRACT

Stevens–Johnson syndrome and toxic epidermal necrolysis (SJS/TEN) are rare type IV hypersensitivity reactions characterized by epidermal necrosis and detachment. We report the case of a preterm newborn at 34 weeks of gestation with gastroschisis who developed extensive blistering skin lesions and mucosal involvement following antibiotic exposure. The diagnosis was confirmed by histopathological examination. Given the rarity of SJS/TEN in the neonatal period and its severe clinical course, this case contributes valuable information for improving diagnostic and therapeutic approaches in similar patients.


REFERENCES

  1. Frantz R, Huang S, Are A, Motaparthi K. Stevens-JohnsonSyndrome and Toxic Epidermal Necrolysis:a review of Diagnosis and Management. Medicina[Internet]. 2021 [consultado el 5 de septiembre de 2025]; (58): 1-15. Disponible en: https://pmc.ncbi.nlm.nih.gov/articles/PMC8472007/pdf/medicina-57-00895.pdf

  2. Sotelo N. Síndrome de Stevens-Johnson y necrólisisepidérmica tóxica en los niños. Artículo de revisión:GacMédMéx [Internet]. 2012 [consultado en 6de septiembre de 2025]; (148): 265-275. Disponibleen: https://www.anmm.org.mx/GMM/2012/n3/GMM_148_2012_3_265-275.pdf

  3. Iriarte C, Karim S, Nassim J, Grnier P, Massey K. InfantileStevens Johnson syndrome and toxic epidermalnecrolysis: A systematic review of clinical featuresand outcomes in children ages 12 months andunder. Pediatric Dermatology [Internet]. 2022 [consultadoel 6 de septiembre de 2025]; 39(6): 876-882.Disponible en: https://onlinelibrary-wiley-com.pbidi.unam.mx:2443/doi/10.1111/pde.15047

  4. Wasuwanich P, So J, Chakrala T, Chen J, MotaparthiK. Epidemiology of Stevens-johnson syndrome andtoxic epidermal necrolysis in the united states andfactors predictive of outcome. JAAD [Internet]. 2023[consultado el 6 de septiembre de 2025]; (13): 17-25.

  5. Micheletti R, et al. Stevens-Johnson Syndrome/To-xic Epidermal Necrolysis: A multicenter retrospectivestudy of 377 adult patients from the United States.[Internet]. 2018 [consultado el 9 de septiembrede 2025]; 138(11): 2315-2321. Disponible en: https://doi.org/10.1016/j.jid.2018.04.027

  6. Abe R, Shibaki A, Nakamura H, Watanabe H, ShimizuH. Toxic epidermal necrolysis and Stevens-Johnsonsyndrome are induced by soluble fas ligand. Am JPathol [Internet]. 2003 [consultado el 9 de septiembrede 2025]; 162(5): 1515-1520.

  7. Viard I, et al. Inhibition of toxic epidermal necrolysisby blockade of CD95 with human intravenous immunoglobulin.Science [Internet]. 1998 [consultado el 9de septiembre de 2025]. 282(5399); 490-493.

  8. Rajesh K, Anupam D, Sudip D. Management ofStevens-Johnson Syndrome–Toxic Epidermal Necrolysis:looking beyond guidlines! Indian J Dermatol[Internet]. 2018 [consultado el 9 de septiembrede 2025]; 63(2): 117-124. Disponible en: https://doi.org/10.4103/ijd.ijd_583_17

  9. Bastuji G, Rzany B, Stern R, Shear N, Naldi L, Rou-Jeau J. Clinical clasification of cases of toxic epidermalnecrolysis, Stevens-Johnson syndrome, anderythema multiforme. Arch Dermatol [Internet]. 1993[consultado el 9 de septiembre de 2025]; 129(1):92-96. Disponible en: https://pubmed.ncbi.nlm.nih.gov/8420497/

  10. McCullough M, Burg M, Lin E, Garner W. Steven JohnsonSyndrome and toxic epidermal necrolysis in aburn unit: a 15 year experience. Burn [Internet]. 2017[consultado el 10 de septiembre de 2025]; 43: 200-205. Disponible en: https://pubmed.ncbi.nlm.nih.gov/27554629/




2020     |     www.medigraphic.com